Published in Cochrane Database Syst Rev on February 16, 2011
Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet (2015) 3.38
Methodology in conducting a systematic review of systematic reviews of healthcare interventions. BMC Med Res Methodol (2011) 2.59
[Safety of immunosuppressants]. Z Rheumatol (2012) 1.98
Managing cytokine release syndrome associated with novel T cell-engaging therapies. Cancer J (2014) 1.64
Colon tuberculosis: endoscopic features and prospective endoscopic follow-up after anti-tuberculosis treatment. Clin Transl Gastroenterol (2012) 1.41
Validity of data collected in BIOREG, the Austrian register for biological treatment in rheumatology: current practice of bDMARD therapy in rheumatoid arthritis in Austria. BMC Musculoskelet Disord (2016) 1.40
Regulatory macrophages: setting the threshold for therapy. Eur J Immunol (2011) 1.40
Challenges and approaches for the development of safer immunomodulatory biologics. Nat Rev Drug Discov (2013) 1.35
Biologic therapy for autoimmune diseases: an update. BMC Med (2013) 1.23
Safety of biologic therapy in rheumatoid arthritis. Nat Rev Rheumatol (2011) 1.22
Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr (2014) 1.19
Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis (2012) 1.13
Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis. Arthritis Rheum (2012) 1.10
Biologic agents in rheumatology: unmet issues after 200 trials and $200 billion sales. Nat Rev Rheumatol (2013) 1.07
Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int (2013) 1.06
Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis. Arthritis Res Ther (2011) 1.05
Interleukin 6 and rheumatoid arthritis. Biomed Res Int (2014) 1.00
TNF inhibitor therapy for rheumatoid arthritis. Biomed Rep (2012) 0.99
IL-7- and IL-15-mediated TCR sensitization enables T cell responses to self-antigens. J Immunol (2013) 0.99
Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature. Immunotherapy (2013) 0.99
The Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic Diseases. Open Rheumatol J (2012) 0.97
Tocilizumab in the treatment of rheumatoid arthritis and beyond. Drug Des Devel Ther (2014) 0.97
Interactions among Low Dose of Methotrexate and Drugs Used in the Treatment of Rheumatoid Arthritis. Adv Pharmacol Sci (2013) 0.96
Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors. Biologics (2014) 0.95
Methods used to conduct and report Bayesian mixed treatment comparisons published in the medical literature: a systematic review. BMJ Open (2013) 0.94
Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant (2012) 0.94
Anti-Interleukin-1 Agents in Adult Onset Still's Disease. Int J Inflam (2012) 0.93
Rituximab and cytokine release syndrome. Case Rep Oncol (2012) 0.93
Treatment of juvenile idiopathic arthritis: a revolution in care. Pediatr Rheumatol Online J (2014) 0.93
Are biologic treatments a potential approach to wear- and corrosion-related problems? Clin Orthop Relat Res (2014) 0.92
Clinical characteristics and treatment responses of patients who developed tuberculosis following use of a tumor necrosis factor-α inhibitor. Korean J Intern Med (2013) 0.90
Update on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials. Ann Rheum Dis (2013) 0.90
Cancer risk of anti-TNF-α at recommended doses in adult rheumatoid arthritis: a meta-analysis with intention to treat and per protocol analyses. PLoS One (2012) 0.89
Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. J Invest Dermatol (2015) 0.89
Network meta-analysis for comparing treatment effects of multiple interventions: an introduction. Rheumatol Int (2014) 0.88
Rheumatoid arthritis and the era of biologic therapy. Inflammopharmacology (2012) 0.88
Safety and efficacy of tocilizumab for the treatment of rheumatoid arthritis. Clin Med Insights Arthritis Musculoskelet Disord (2012) 0.87
Novel, biocompatible, and disease modifying VIP nanomedicine for rheumatoid arthritis. Mol Pharm (2013) 0.87
A(2A) adenosine receptors are differentially modulated by pharmacological treatments in rheumatoid arthritis patients and their stimulation ameliorates adjuvant-induced arthritis in rats. PLoS One (2013) 0.87
Tumor necrosis factor inhibitors - state of knowledge. Arch Med Sci (2014) 0.87
Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. Pharmacoeconomics (2014) 0.86
Time trends in total ankle arthroplasty in the USA: a study of the National Inpatient Sample. Clin Rheumatol (2014) 0.85
Biologics in the management of ulcerative colitis - comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag (2015) 0.85
Complications of immunosuppressive/immunomodulatory therapy in neurological diseases. Curr Treat Options Neurol (2012) 0.85
Patterns of use and dosing of tocilizumab in the treatment of patients with rheumatoid arthritis in routine clinical practice: the ACT-LIFE study. Rheumatol Int (2015) 0.84
Anti-TNF-alpha therapy and systemic vasculitis. Mediators Inflamm (2014) 0.84
Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology (Oxford) (2013) 0.84
Abatacept (cytotoxic T lymphocyte antigen 4-immunoglobulin) improves B cell function and regulatory T cell inhibitory capacity in rheumatoid arthritis patients non-responding to anti-tumour necrosis factor-α agents. Clin Exp Immunol (2014) 0.83
Potential patient benefit of a subcutaneous formulation of tocilizumab for the treatment of rheumatoid arthritis: a critical review. Patient Prefer Adherence (2014) 0.82
Drug adherence to biologic DMARDS with a special emphasis on the benefits of subcutaneous abatacept. Patient Prefer Adherence (2012) 0.82
Safety of tumor necrosis factor inhibitors use for rheumatoid arthritis and ankylosing spondylitis in Africa, the Middle East, and Asia: focus on severe infections and tuberculosis. Clin Rheumatol (2012) 0.81
The role of mucosal healing in the treatment of patients with inflammatory bowel disease. Curr Treat Options Gastroenterol (2014) 0.81
Immunosuppressive drugs and fertility. Orphanet J Rare Dis (2015) 0.81
Nanotherapeutic approaches for the treatment of rheumatoid arthritis. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.80
Abatacept and its use in the treatment of rheumatoid arthritis (RA) in the Czech Republic-data from the ATTRA registry. Clin Rheumatol (2013) 0.80
Management of rheumatoid arthritis in People's Republic of China - focus on tocilizumab and patient considerations. Int J Gen Med (2015) 0.80
From historical perspectives to modern therapy: a review of current and future biological treatments for Crohn's disease. Therap Adv Gastroenterol (2015) 0.80
Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus. Clin Dev Immunol (2013) 0.79
Head-to-head comparison of the safety of tocilizumab and tumor necrosis factor inhibitors in rheumatoid arthritis patients (RA) in clinical practice: results from the registry of Japanese RA patients on biologics for long-term safety (REAL) registry. Arthritis Res Ther (2015) 0.79
Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study. BMC Infect Dis (2013) 0.79
Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom. Clin Rheumatol (2015) 0.78
Infliximab to treat Crohn's disease: an update. Clin Exp Gastroenterol (2011) 0.78
Systemic treatments for noninfectious vitreous inflammation. Mediators Inflamm (2013) 0.78
Safety of biologics in rheumatoid arthritis: data from randomized controlled trials and registries. Biologics (2015) 0.78
Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective. Crit Care (2012) 0.78
Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece. Rheumatol Int (2015) 0.78
A medicoeconomic review of early intervention with biologic agents in the treatment of inflammatory bowel diseases. Clinicoecon Outcomes Res (2014) 0.78
Accelerated infliximab infusions for inflammatory bowel disease improve effectiveness. World J Gastrointest Pharmacol Ther (2012) 0.78
bDMARD Dose Reduction in Rheumatoid Arthritis: A Narrative Review with Systematic Literature Search. Rheumatol Ther (2017) 0.77
A Personalized Approach to Biological Therapy Using Prediction of Clinical Response Based on MRP8/14 Serum Complex Levels in Rheumatoid Arthritis Patients. PLoS One (2016) 0.77
Drug-induced liver injury caused by adalimumab: a case report and review of the bibliography. Case Reports Hepatol (2013) 0.77
Tocilizumab in rheumatoid arthritis: efficacy, safety and its place in therapy. Ther Adv Chronic Dis (2013) 0.77
Efficacy of biological agents administered as monotherapy in rheumatoid arthritis: a Bayesian mixed-treatment comparison analysis. Ther Clin Risk Manag (2015) 0.77
On the criteria used for assessing the risk of bias in randomized trials included in systematic reviews and meta-analyses addressing adverse effects. Eur J Epidemiol (2015) 0.77
Objective measurement of erythema in psoriasis using digital color photography with color calibration. Skin Res Technol (2015) 0.77
Biological drugs for the treatment of rheumatoid arthritis by the subcutaneous route: interpreting efficacy data to assess statistical equivalence. Ther Adv Musculoskelet Dis (2014) 0.76
Elderly patients and inflammatory bowel disease. World J Gastrointest Pharmacol Ther (2016) 0.76
The Role of Laboratory Tests in Crohn's Disease. Clin Med Insights Gastroenterol (2016) 0.76
Biologic therapies and infections in the daily practice of three Italian rheumatologic units: a prospective, observational study. Clin Rheumatol (2016) 0.76
Periprocedural adverse events in cell therapy trials in myocardial infarction and cardiomyopathy: a systematic review. Clin Res Cardiol (2012) 0.75
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of rheumatoid arthritis in England and Wales: addressing treatment outside the current NICE guidance. Clin Rheumatol (2012) 0.75
RAC1 activation drives pathologic interactions between the epidermis and immune cells. J Clin Invest (2016) 0.75
Nanomedicines for chronic non-infectious arthritis: the clinician's perspective. Nanomedicine (2012) 0.75
Squamous-cell carcinoma of the tongue following therapy of rheumatoid arthritis with abatacept. Clin Case Rep (2014) 0.75
Use of biologics in a patient with rheumatoid arthritis refractory to methotrexate. CMAJ (2013) 0.75
New prospects in the diagnosis and treatment of immune-mediated inner ear disease. World J Methodol (2014) 0.75
Systemic treatment of vitreous inflammation. Mediators Inflamm (2012) 0.75
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? World J Gastrointest Pharmacol Ther (2016) 0.75
A Potential 'Curative' Modality for Crohn's Disease---Modeled after Prophylaxis of Bovine Johne's Disease. Mycobact Dis (2012) 0.75
Ankylosing spondylitis combined with angioimmunoblastic T cell lymphoma. BMJ Case Rep (2011) 0.75
Successful resumption of tocilizumab for rheumatoid arthritis after resection of a pulmonary Mycobacterium avium complex lesion: a case report. BMC Pulm Med (2015) 0.75
IL-6 blockade in chronic inflammatory diseases. Wien Med Wochenschr (2014) 0.75
Room for more IL-6 blockade? Sarilumab for the treatment of rheumatoid arthritis. Expert Opin Biol Ther (2016) 0.75
Adherence to guidelines in the use of biological agents to treat psoriasis in Brazil. BMJ Open (2014) 0.75
Biological drugs for the treatment of psoriasis in a public health system. Rev Saude Publica (2014) 0.75
Direct Comparative Effectiveness Among 3 Anti-Tumor Necrosis Factor Biologics in a Real-Life Cohort of Patients With Rheumatoid Arthritis. J Clin Rheumatol (2016) 0.75
Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 41.47
Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet (2012) 26.95
Grading quality of evidence and strength of recommendations. BMJ (2004) 26.08
Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol (2007) 13.46
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA (2006) 11.71
Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet (2012) 11.32
GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol (2011) 10.02
American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) (2012) 9.25
Randomized trials stopped early for benefit: a systematic review. JAMA (2005) 8.43
Developing core outcome sets for clinical trials: issues to consider. Trials (2012) 8.39
Cardiac-resynchronization therapy for mild-to-moderate heart failure. N Engl J Med (2010) 8.28
Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. Ann Intern Med (2007) 7.99
Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis (2010) 7.60
Large-scale association analysis identifies new risk loci for coronary artery disease. Nat Genet (2012) 7.59
Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res (2004) 7.20
Campaign to revitalise academic medicine kicks off. BMJ (2004) 6.94
High-frequency oscillation in early acute respiratory distress syndrome. N Engl J Med (2013) 6.56
Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med (2013) 6.40
A genome-wide meta-analysis identifies 22 loci associated with eight hematological parameters in the HaemGen consortium. Nat Genet (2009) 6.31
American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum (2011) 6.28
AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews. J Clin Epidemiol (2009) 6.00
Stopping randomized trials early for benefit and estimation of treatment effects: systematic review and meta-regression analysis. JAMA (2010) 5.90
GRADE guidelines: a new series of articles in the Journal of Clinical Epidemiology. J Clin Epidemiol (2010) 5.78
Probiotics for the prevention of Clostridium difficile-associated diarrhea: a systematic review and meta-analysis. Ann Intern Med (2012) 5.67
Comparison of mortality between private for-profit and private not-for-profit hemodialysis centers: a systematic review and meta-analysis. JAMA (2002) 5.57
A Trial of Wound Irrigation in the Initial Management of Open Fracture Wounds. N Engl J Med (2015) 5.28
The global burden of low back pain: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis (2014) 5.19
Grading quality of evidence and strength of recommendations for diagnostic tests and strategies. BMJ (2008) 5.16
A systematic review and meta-analysis of studies comparing mortality rates of private for-profit and private not-for-profit hospitals. CMAJ (2002) 4.84
High risk clinical characteristics for subarachnoid haemorrhage in patients with acute headache: prospective cohort study. BMJ (2010) 4.65
A systematic review of the global prevalence of low back pain. Arthritis Rheum (2012) 4.64
The Canadian C-spine rule versus the NEXUS low-risk criteria in patients with trauma. N Engl J Med (2003) 4.48
Who cares about academic medicine? BMJ (2004) 4.46
Internet versus mailed questionnaires: a randomized comparison (2). J Med Internet Res (2004) 4.45
The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med (2009) 4.41
Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet (2012) 4.36
Comparison of the Canadian CT Head Rule and the New Orleans Criteria in patients with minor head injury. JAMA (2005) 4.35
Clinical decision rules to rule out subarachnoid hemorrhage for acute headache. JAMA (2013) 4.34
Need for expertise based randomised controlled trials. BMJ (2005) 4.34
An observational study of orthopaedic abstracts and subsequent full-text publications. J Bone Joint Surg Am (2002) 4.25
American College of Rheumatology/European League against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Ann Rheum Dis (2011) 4.15
Derivation of the San Francisco Syncope Rule to predict patients with short-term serious outcomes. Ann Emerg Med (2004) 4.12
Advanced cardiac life support in out-of-hospital cardiac arrest. N Engl J Med (2004) 4.09
Open letter to the leader of academic medicine. BMJ (2007) 4.06
CATCH: a clinical decision rule for the use of computed tomography in children with minor head injury. CMAJ (2010) 4.03
Fluid resuscitation in sepsis: a systematic review and network meta-analysis. Ann Intern Med (2014) 3.96
Five futures for academic medicine. PLoS Med (2005) 3.95
Treatment of lateral epicondylitis with platelet-rich plasma, glucocorticoid, or saline: a randomized, double-blind, placebo-controlled trial. Am J Sports Med (2013) 3.89
Developing theory-informed behaviour change interventions to implement evidence into practice: a systematic approach using the Theoretical Domains Framework. Implement Sci (2012) 3.81
Combined corticosteroid and antiviral treatment for Bell palsy: a systematic review and meta-analysis. JAMA (2009) 3.81
A new 'mechanistic-practical" framework for designing and interpreting randomized trials. J Clin Epidemiol (2008) 3.75
Effectiveness of vertebroplasty using individual patient data from two randomised placebo controlled trials: meta-analysis. BMJ (2011) 3.69
Vertebroplasty appears no better than placebo for painful osteoporotic spinal fractures, and has potential to cause harm. Med J Aust (2009) 3.69
The reporting of methodological factors in randomized controlled trials and the association with a journal policy to promote adherence to the Consolidated Standards of Reporting Trials (CONSORT) checklist. Control Clin Trials (2002) 3.62
Physicians' and patients' choices in evidence based practice. BMJ (2002) 3.57
Evidence-based clinical guidelines for immigrants and refugees. CMAJ (2010) 3.57
Is a subgroup effect believable? Updating criteria to evaluate the credibility of subgroup analyses. BMJ (2010) 3.54
Meta-analyses of therapies for postmenopausal osteoporosis. IX: Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev (2002) 3.46
A citywide protocol for primary PCI in ST-segment elevation myocardial infarction. N Engl J Med (2008) 3.44
Barriers to full-text publication following presentation of abstracts at annual orthopaedic meetings. J Bone Joint Surg Am (2003) 3.36
Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol (2002) 3.36
Validity of composite end points in clinical trials. BMJ (2005) 3.26
Quality of care in for-profit and not-for-profit nursing homes: systematic review and meta-analysis. BMJ (2009) 3.22
Design of the Coronary ARtery DIsease Genome-Wide Replication And Meta-Analysis (CARDIoGRAM) Study: A Genome-wide association meta-analysis involving more than 22 000 cases and 60 000 controls. Circ Cardiovasc Genet (2010) 3.15
Internal fixation compared with arthroplasty for displaced fractures of the femoral neck. A meta-analysis. J Bone Joint Surg Am (2003) 3.14
Effect of early surgery after hip fracture on mortality and complications: systematic review and meta-analysis. CMAJ (2010) 3.13
The Canadian C-spine rule performs better than unstructured physician judgment. Ann Emerg Med (2003) 3.12
Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev (2008) 3.08
Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol (2003) 3.07
Gene dosage of the common variant 9p21 predicts severity of coronary artery disease. J Am Coll Cardiol (2010) 3.07
Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ (2007) 3.06
Quality of life of individuals with heart failure: a randomized trial of the effectiveness of two models of hospital-to-home transition. Med Care (2002) 3.05
Corticosteroid Therapy for Patients Hospitalized With Community-Acquired Pneumonia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 2.95
Accuracy of magnetic resonance imaging for the diagnosis of multiple sclerosis: systematic review. BMJ (2006) 2.95
A consensus approach toward the standardization of back pain definitions for use in prevalence studies. Spine (Phila Pa 1976) (2008) 2.94
Does ratification of human-rights treaties have effects on population health? Lancet (2009) 2.93
Telecare for patients with type 1 diabetes and inadequate glycemic control: a randomized controlled trial and meta-analysis. Diabetes Care (2004) 2.93
Systems for grading the quality of evidence and the strength of recommendations II: pilot study of a new system. BMC Health Serv Res (2005) 2.91
Oral direct Factor Xa inhibitors versus low-molecular-weight heparin to prevent venous thromboembolism in patients undergoing total hip or knee replacement: a systematic review and meta-analysis. Ann Intern Med (2012) 2.91
Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. Arch Intern Med (2007) 2.82
Assessing risk of bias in prevalence studies: modification of an existing tool and evidence of interrater agreement. J Clin Epidemiol (2012) 2.81
BIPHASIC Trial: a randomized comparison of fixed lower versus escalating higher energy levels for defibrillation in out-of-hospital cardiac arrest. Circulation (2007) 2.80
What types of interventions generate inequalities? Evidence from systematic reviews. J Epidemiol Community Health (2012) 2.80
Progress in evidence-based medicine. JAMA (2008) 2.77
Payments for care at private for-profit and private not-for-profit hospitals: a systematic review and meta-analysis. CMAJ (2004) 2.76
Clinical outcomes following institution of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA (2003) 2.74
Time-dependent bias was common in survival analyses published in leading clinical journals. J Clin Epidemiol (2004) 2.70
Lack of evidence for use of glatiramer acetate in multiple sclerosis. Lancet Neurol (2004) 2.70
Credibility of claims of subgroup effects in randomised controlled trials: systematic review. BMJ (2012) 2.69
Specific instructions for estimating unclearly reported blinding status in randomized trials were reliable and valid. J Clin Epidemiol (2011) 2.69